{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:05:59Z","timestamp":1790456759840,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T00:00:00Z","timestamp":1370995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T00:00:00Z","timestamp":1370995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10637-013-9966-3","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T06:09:02Z","timestamp":1370930942000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Prasanth","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shell","family":"Laday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agop Y.","family":"Bedikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill","family":"Kies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,12]]},"reference":[{"issue":"1\u20132","key":"9966_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1\u20132):56\u201363","journal-title":"Microvasc Res"},{"issue":"1","key":"9966_CR2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380\u2013386","journal-title":"J Immunol"},{"issue":"3","key":"9966_CR3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/jpet.102.048496","volume":"305","author":"PH Schafer","year":"2003","unstructured":"Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305(3):1222\u20131232","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"9966_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00280-012-1874-2","volume":"69","author":"A Segler","year":"2012","unstructured":"Segler A, Tsimberidou AM (2012) Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69(6):1393\u20131406","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl","key":"9966_CR5","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/jco.2009.27.15_suppl.5156","volume":"7","author":"D Petrylak","year":"2009","unstructured":"Petrylak D, Resto-Garces K, Tibyan M, Mohile S (2009) A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol 7(suppl), abstr 5156","journal-title":"J Clin Oncol"},{"issue":"24 Pt 2","key":"9966_CR6","first-page":"215","volume":"11","author":"K Papadopoulos","year":"2005","unstructured":"Papadopoulos K, Mendelson D, Preston G (2005) A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors. Clin Cancer Res: Abstr Int Conf Mol Targets Cancer Ther 11(24 Pt 2):215","journal-title":"Clin Cancer Res: Abstr Int Conf Mol Targets Cancer Ther"},{"issue":"10","key":"9966_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5(10):835\u2013844","journal-title":"Nat Rev Drug Discov"},{"key":"9966_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1479-5876-5-38","volume":"5","author":"DP Mangiameli","year":"2007","unstructured":"Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK (2007) Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 5:38","journal-title":"J Transl Med"},{"key":"9966_CR9","unstructured":"Institute NC (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed December 18 2012"},{"issue":"3","key":"9966_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"9966_CR11","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","volume":"24","author":"MJ Ratain","year":"2006","unstructured":"Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O\u2019Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505\u20132512","journal-title":"J Clin Oncol"},{"issue":"14","key":"9966_CR12","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.ejca.2006.05.018","volume":"42","author":"RA Sharma","year":"2006","unstructured":"Sharma RA, Steward WP, Daines CA, Knight RD, O\u2019Byrne KJ, Dalgleish AG (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42(14):2318\u20132325","journal-title":"Eur J Cancer"},{"issue":"5","key":"9966_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43\u20139006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965\u2013972","journal-title":"J Clin Oncol"},{"issue":"2","key":"9966_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134","journal-title":"N Engl J Med"},{"issue":"4","key":"9966_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"4","key":"9966_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426\u2013437","journal-title":"Oncologist"},{"issue":"1","key":"9966_CR17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","volume":"116","author":"T Eisen","year":"2010","unstructured":"Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J (2010) Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146\u2013154","journal-title":"Cancer"},{"issue":"22","key":"9966_CR18","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1002\/cncr.24576","volume":"115","author":"J Glaspy","year":"2009","unstructured":"Glaspy J, Atkins MB, Richards JM, Agarwala SS, O\u2019Day S, Knight RD, Jungnelius JU, Bedikian AY (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115(22):5228\u20135236","journal-title":"Cancer"},{"issue":"3","key":"9966_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/COC.0b013e31815e4505","volume":"31","author":"RJ Amato","year":"2008","unstructured":"Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31(3):244\u2013249","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"9966_CR20","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/cncr.22290","volume":"107","author":"TK Choueiri","year":"2006","unstructured":"Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609\u20132616","journal-title":"Cancer"},{"issue":"1","key":"9966_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","volume":"102","author":"C Bengala","year":"2010","unstructured":"Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102(1):68\u201372","journal-title":"Br J Cancer"},{"issue":"12","key":"9966_CR22","doi-asserted-by":"publisher","first-page":"e15588","DOI":"10.1371\/journal.pone.0015588","volume":"5","author":"PA Ott","year":"2010","unstructured":"Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC (2010) A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 5(12):e15588","journal-title":"PLoS One"},{"issue":"7","key":"9966_CR23","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1148\/rg.317115108","volume":"31","author":"RG Figueiras","year":"2011","unstructured":"Figueiras RG, Padhani AR, Goh VJ, Vilanova JC, Gonzalez SB, Martin CV, Caamano AG, Naveira AB, Choyke PL (2011) Novel oncologic drugs: what they do and how they affect images. Radiographics 31(7):2059\u20132091","journal-title":"Radiographics"},{"issue":"5","key":"9966_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/cncr.26413","volume":"118","author":"I Garrido-Laguna","year":"2012","unstructured":"Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012) Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 118(5):1422\u20131428","journal-title":"Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9966-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9966-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9966-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9966-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T05:47:58Z","timestamp":1715492878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9966-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9966"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9966-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,12]]},"assertion":[{"value":"15 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}